Trial Profile
A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2020 Status changed from completed to discontinued.
- 11 Oct 2019 Status changed from recruiting to completed.
- 20 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 30 Sep 2019.